glp 1 cardiovascular risk reduction Patients with diabetes who remained on GLP-1 drugs had lower Cardiovascular disease continuum-GLP-1 action. Adapted

Diabetologia 2018;61:218

By acting as a hepatocyte growth factor (HGF)/c-Met agonist, it promotes neuroplasticity, memory formation, and potential repair of damaged neural circuits

But thats a topic for a future article

The key distinction in this research area: stimulating the bodys own GH production is mechanistically different from injecting synthetic HGH directly

Sources: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Gastroparesis Information Page: Mayo Clinic - Gastroparesis: American College of Gastroenterology - Gastroparesis: Bloomberg - FDA Warns of Gastroparesis Risk With Novo Nordisk's Ozempic:

NeuroReport 29 , 833838